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Chemotherapy resistance associated with recurrent disease is the major cause of poor
survival of ovarian cancer patients. We have recently demonstrated activation of the
JAK2/STAT3 pathway and the enhancement of a cancer stem cell (CSC)-like phenotype
in ovarian cancer cells treated in vitro with chemotherapeutic agents. To elucidate further
these mechanisms in vivo, we used a two-tiered paclitaxel treatment approach in nude mice
inoculated with ovarian cancer cells. In the first approach, we demonstrate that a single
intraperitoneal administration of paclitaxel in mice 7 days after subcutaneous transplanta-
tion of the HEY ovarian cancer cell line resulted in a significant increase in the expression of
CA125, Oct4, and CD117 in mice xenografts compared to control mice xenografts which did
not receive paclitaxel. In the second approach, mice were administered once weekly with
paclitaxel and/or a daily dose of the JAK2-specific inhibitor, CYT387, over 4 weeks. Mice
receiving paclitaxel only demonstrated a significant decrease in tumor volume compared
to control mice. At the molecular level, mouse tumors remaining after paclitaxel adminis-
tration showed a significant increase in the expression of Oct4 and CD117 coinciding with
a significant activation of the JAK2/STAT3 pathway compared to control tumors. The addi-
tion of CYT387 with paclitaxel resulted in the suppression of JAK2/STAT3 activation and
abrogation of Oct4 and CD117 expression in mouse xenografts. This coincided with signif-
icantly smaller tumors in mice administered CYT387 in addition to paclitaxel, compared to
the control group and the group of mice receiving paclitaxel only. These data suggest that
the systemic administration of paclitaxel enhances Oct4- and CD117-associated CSC-like
marker expression in surviving cancer cells in vivo, which can be suppressed by the addi-
tion of the JAK2-specific inhibitor CYT387, leading to a significantly smaller tumor burden.
These novel findings have the potential for the development of CSC-targeted therapy to
improve the treatment outcomes of ovarian cancer patients.
Keywords: ovarian carcinoma, cancer stem cells, metastasis, chemoresistance, recurrence, JAK2/STAT3 pathway
INTRODUCTION
The gold standard for the management of ovarian cancer patients
after debulking surgery is the systemic administration of platinum
(cisplatin/carboplatin) and taxane-based (paclitaxel) drugs. This
treatment regimen results in a significant reduction of tumor bur-
den due to substantial cancer cell death via DNA and cytoskeletal
damage response pathways (1). Most of the ovarian cancer patients
(~80%) respond well to the standard treatment regimen and enjoy
a short-lived period of remission with asymptomatic minimal dis-
ease. However, this asymptomatic microscopic residual disease
persisting after the first line chemotherapy leads to consecutive
episodes of recurrent disease and eventual death. Hence, the 5-
year survival period of ovarian cancer patients is as low as ~30%
(2, 3). Thus, to increase the survival rate of ovarian cancer patients,
there is an urgent need to identify the mechanisms that allow resid-
ual tumor cells to overcome first line chemotherapy and propagate
within the changed tumor microenvironment.
Chemoresistant tumor cells that have the ability to resist the
cytotoxic effects of chemotherapy have high expression of mul-
tidrug resistance transporters, enhanced ability to repair damaged
DNA, and proliferate slowly (4). Recent studies have shown these
phenotypes to be commonly displayed by cancer stem cells (CSCs)
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(5, 6). A few recent studies have also demonstrated enrichment
in CSCs and stem cell mediator pathways in chemoresistant and
recurrent ovarian tumors, suggesting that CSCs and their associ-
ated pathways may be important intermediaries in the emergence
of disease recurrence (7–10).
Several cell signaling pathways have been associated with self-
renewal and the tumorigenic phenotype of CSCs. The Wnt, Sonic
Hedgehog (Shh), and the Notch signaling pathways have been
shown to be the drivers for the progression of cancers, includ-
ing ovarian cancer (11–13). Another signaling pathway that is
implicated in ovarian as well as other solid cancers is the signal
transducer and activator of transcription protein 3 (STAT3) (14–
16). In normal cells, STAT3 is transiently activated in response to
specific growth factors and cytokines [interleukin-6 (IL-6), gran-
ulocyte colony stimulating factor (G-CSF), leukemia inhibitory
factor (LIF), epidermal growth factor (EGF), etc]. However, in
cancers, including breast, ovarian, and prostate, STAT3 is con-
stitutively active in some cancer cells (17), and is believed to be
responsible for several key points in tumor progression, start-
ing from uncontrolled cellular proliferation to the promotion
of angiogenesis and importantly facilitating resistance to apop-
tosis induced by conventional chemotherapy (18, 19). STAT3 is
also involved in integrating the signals received from a variety of
external agents such as growth factors or cytokines or genotoxic
stressors and mediates the response of such agents by regulating
downstream gene expression linked with cell survival and other
cellular functions (20–22). Moreover, the STAT3 pathway has been
shown to be a requisite for the proliferation and maintenance of
glioblastoma stem cells (23), as well as rapidly cycling intestinal
stem cells (24).
Recent studies have shown a link between the activation of
STAT3 and CSCs. Coupling of the stem cell marker CD44 with
the embryonic stem cell marker Nanog has been shown to be
associated with the activation of STAT3 in ovarian cancer cells
(25). The activation of STAT3 in these cells resulted in multidrug
resistance gene expression and concomitant chemoresistance. Fur-
thermore, we have previously demonstrated sustained activation
of the STAT3 pathway in advanced-stage ovarian tumors and in
cisplatin-treated ovarian cancer cell lines (15, 26). A recent study
has shown significantly enhanced activation of STAT3 sustained
by infiltrating macrophages in drug-resistant recurrent ovarian
tumors compared to the matched primary tumors (27). Hence, the
JAK2/STAT3 pathway is a potential target for the development of
novel drugs aimed at suppressing its constitutive as well as ligand-
induced activation. In the last decade, several anti-STAT3 small
molecule inhibitors have shown promising potential by coun-
teracting cancer cell-associated proliferation, inflammation, and
importantly chemoresistance (17, 28). However, none of these
compounds have been shown to have an effect on CSCs, which
theoretically have been suggested to drive chemoresistance.
We have previously demonstrated that the in vitro treatment of
OVCA 433 and HEY cell lines with cisplatin or paclitaxel resulted
in the activation of the JAK2/STAT3 pathway (7, 26). We have
also shown that intraperitoneal transplantation of chemotherapy-
treated cells in nude mice resulted in a significantly higher tumor
burden associated with enhanced CSC-like expression compared
to control untreated cells (29). In the study reported here, we
aimed to determine the effect of a novel small molecule inhibitor of
the JAK2/STAT3 pathway, CYT387, in combination with systemic
administration of paclitaxel and assess the molecular phenotype
of the resultant xenografts. We demonstrate that irrespective of
the length of paclitaxel treatment, systemic administration of
paclitaxel enhanced the expression of Oct4 and CD117 in resid-
ual tumors. However, administration of CYT387 (by daily oral
gavages) in combination with weekly systemic paclitaxel adminis-
tration resulted in a significantly reduced tumor volume compared
to control and paclitaxel alone treatment mice. These tumors dis-
played diminished JAK2/STAT3 activation as well as diminished
Oct4 and CD117 expression compared to tumors generated during
systemic administration of paclitaxel only. These novel data sug-
gest that the inclusion of a JAK2/STAT3 inhibitor such as CYT387
with paclitaxel has the potential of reducing the tumor volume
further than that achieved by using chemotherapy alone. Such
observations in animal models provide“proof of concept”demon-
strating the potential of CYT387 in reducing the intraperitoneal
tumor burden in ovarian cancer patients further than that achieved
by paclitaxel on its own. This may provide the patients with a lower
or/zero incidence of tumor recurrence or longer disease-free sur-
vival period, and better quality of life so lacking following the
current treatment options in these patients.
MATERIALS AND METHODS
CELL LINES
The human ovarian HEY cell line was derived from a peritoneal
deposit of a patient diagnosed with papillary cystadenocarcinoma
of the ovary (30). The cell line was grown as described previously
(29, 31).
ANTIBODIES AND REAGENTS
Polyclonal antibody against phosphorylated (Tyr-705) STAT3 (P-
STAT3), total STAT3 (T-STAT3), phosphorylated (Tyr-1007/1008)
JAK2 (P-JAK2), and total JAK2 (T-JAK2) were obtained from
Cell Signaling Technology (Beverly, MA, USA). Antibodies against
cytokeratin 7 (cyt7), Ki67, CA125, E-cadherin, vimentin, CD34,
Oct4, and CD117 (c-Kit) used for immunohistochemistry were
obtained from Ventana (Roche, AZ, USA). CYT387 [Momelotinib
(GS-0387/CYT-0387)] was obtained from Gilead Sciences (CA,
USA).
RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR
Tumors obtained from mice were homogenized and cells lysed
prior to RNA extractions and cDNA synthesis as described
previously (29). For quantitative real-time PCR (q-PCR), four
tumors in each group [control, paclitaxel-treated, CYT387-treated,
and paclitaxel+CYT387-treated] were analyzed in triplicate as
described previously (32). Each gene was validated by using an
amplified, purified, and sequenced PCR fragment (originating
from HEY cell line) as a positive control. The primers used for
18S, Oct-4A, IL-6, interleukin-6 receptor (IL-6R), glycoprotein
130 (gp130), C-X-C chemokine receptor type 4 (CXCR4), matrix
metalloproteinase 2 (MMP-2), and matrix metalloproteinase 9
(MMP-9) are described in Table 1. q-PCR was carried out using
ViiA 7 real-time PCR system (Applied Biosystems). Relative gene
expression was calculated as 2−∆∆Ct using 18S as the endogenous
reference gene and the average of the controls as the calibrator.
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Table 1 | Human oligonucleotide primer sequences for quantitative
real-time PCR.
Gene
symbol
Accession no. Primer sequences from 5′ to 3′ Size
(bp)
RNA18S NR 003286.2 Forward GTAACCCGTTGAACCCCATT 153
Reverse CCATCCAATCGGTAGTAGCG
POU5F1 NM 002701.4 Forward CTCCTGGAGGGCCAGGAATC 381
(OCT4A) Reverse CCACATCGGCCTGTGTATAT
IL6 NM 000600.3 Forward TACCCCCAGGAGAAGATTCC 175
Reverse TTTTCTGCCAGTGCCTCTTT
IL6R NM 000565.3 Forward CTCCTGCCAGTTAGCAGTCC 198
Reverse TCTTGCCAGGTGACACTGAG
IL6ST NM 002184.3 Forward TGTAGATGGCGGTGATGGTA 246
(gp130) Reverse CCCTCAGTACCTGGACCAAA
CXCR4 NM 001008540.1 Forward GAAGCTGTTGGCTGAAAAGG 94
Reverse CTCACTGACGTTGGCAAAGA
MMP2 NM 004530.4 Forward TTGACGGTAAGGACGGACTC 153
Reverse ACTTGCAGTACTCCCCATCG
MMP9 NM 004994.2 Forward TTGACAGCGACAAGAAGTGG 179
Reverse GCCATTCACGTCGTCCTTAT
ANIMAL STUDIES
Animal ethics statement
This study was carried out in strict accordance with the recom-
mendations in the Guide for the Care and Use of the Laboratory
Animals of the National Health and Medical Research Coun-
cil of Australia. The experimental protocol was approved by the
Ludwig/Department of Surgery, Royal Melbourne Hospital, and
University of Melbourne’s Animal Ethics Committee (Project-
006/11), and was endorsed by the Research and Ethics Committee
of Royal Women’s Hospital Melbourne, VIC, Australia.
Animal experiments
Female Balb/c nu/nu mice (age, 6–8 weeks) were obtained from the
Animal Resources Centre,Western Australia. Animals were housed
in a standard pathogen-free environment with access to food and
water.
HEY cells (5× 106) were inoculated subcutaneously in each
flank of nude mice as described previously (33). Mice were
inspected weekly and tumor progression was monitored based
on overall health and body weight until one of the pre-determined
endpoints was reached. Endpoint criteria included exceeding 20%
loss of initial body weight and a general pattern of diminished well-
being such as reduced movement due to tumor burden, ulceration
of tumors due to constant irritation of the protruding tumors with
the mouse bedding, and lethargy resulting from lack of interest in
daily activities. As such, the endpoint of the experiment was noted
at day 7 (first approach) or day 28 (second approach) after the start
of paclitaxel and/or CYT387 treatments. The 7- or 28-day dura-
tion was chosen as the tumor volume in the control group reached
the defined volume of end point as specified in the Animal Ethics
application.
In the first approach, mice were divided into two groups with
n= 3 mice in each group and HEY cells were inoculated subcuta-
neously in each flank of nude mice. The first group of mice was
treated as a control. After 7 days, the second group of mice was
treated once intraperitoneally with 15 mg/kg of body weight of
paclitaxel. These mice were followed for 7 days, after which the
experiment was terminated.
In the second approach, mice were divided into four groups
with n= 5 in each group and HEY cells were inoculated subcuta-
neously in each flank of nude mice. The first group of mice was
designated as control. The second group was treated once a week
with an intraperitoneal injection of paclitaxel at 15 mg/kg of body
weight, 2 days post inoculation of the HEY cells. The third group
was treated with the same dose of paclitaxel weekly in addition
to daily doses of CYT387 at 5 mg/kg of body weight by oral gav-
ages. The weekly intraperitoneal injection of paclitaxel and oral
gavages of CYT387 was continued for 28 days. The fourth group
of mice was treated with a daily dose of 5 mg/kg of body weight of
CYT387 by oral gavages for 28 days. Mice were euthanized at the
experimental endpoint and the tumors were excised for further
examination.
Tumor volume measurements were performed with calipers at
day 0 and days 7 and 28 (the experimental endpoint). Measure-
ment of tumor volume in cubic millimeter was determined using
the formula (length×width2)/2; where length was the longest axis
and width was the measurement at right angles to the length (33).
Fold change in tumor volume was calculated from the ratio of
tumor volume at day 0 to day 7 or day 28.
Immunohistochemistry
For immunohistochemistry, formalin-fixed, paraffin-embedded
4µm sections of the xenografts were stained using a Ven-
tana Benchmark Immunostainer (Ventana Medical Systems, Inc.,
AZ, USA) described previously (29). Detection was performed
using Ventana’s ultra view diaminobenzidine (DAB) detection
kit (Roche/Ventana, AZ, USA). Tumor sections were dewaxed
with Ventana EZ Prep and endogenous peroxidase activity was
blocked using the Ventana’s universal DAB inhibitor. Primary
antibodies against Oct4, Ki67, cancer antigen 125 (CA125),
CD117 (c-Kit), total JAK2 (T-JAK2), phospho-JAK2 (P-JAK2),
total STAT3 (T-STAT3), and phospho-STAT3 (P-STAT3) were
diluted according to the instruction provided by the manufac-
turer as described in Table 2. For nuclear staining, the sections
were counter stained with Ventana hematoxylin and bluing solu-
tion. For each antigen, a parallel paraffin-embedded section
was prepared without the primary antibody as a negative con-
trol. High-grade serous ovarian tumor sections were used as
positive controls.
Immunohistochemistry images were created using an Axioskop
2 microscope, captured using a Nikon DXM1200C digital cam-
era and processed using NIS-elements F3.0 software. Slides were
scored independently by four blind reviewers, as described pre-
viously (34). For each slide, the extent of positive staining was
scored as five grades, namely, 0 (≤10%), 1 (>10–25%), 2 (>25–
40%), 3 (≥40–50%), 4 (≥50–75%), and 5 (>75%). The intensity
of staining (IS) was classified into four grades: no staining (−), pale
brown (1), moderate brown (2) and dark brown (3). Scoring was
determined by using the Allred method of visual quantification as
per the following formula: percentage of staining (PS)+ IS= total
score (range 0–8) (35).
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Table 2 | Antibody information.
Antibodies Concentrations used Incubation time Supplier Catalog
(minutes) number
Mouse anti-human Ki67 2µg/ml 12 Ventana 790-4286
Mouse anti-human Oct4 (we use Oct3/4) 1.2µg/ml 32 Novocastra NCL-L-OCT3/4
Mouse anti-human CD34 0.8µg/ml 32 Ventana 790-2927
Mouse Anti-Human CD117 5µg/ml 32 Ventana 790-2951
Rabbit anti-human JAK2 10µg/ml 40 Cell Signaling 3230
Rabbit anti-human Phospho-JAK2 (Tyr1007/1008) (C80C3) 10µg/ml 40 Cell Signaling 3776
Mouse anti-human STAT3 (124H6) 2.5µg/ml 40 Cell Signaling 9139
Mouse anti-human phospho-STAT3 (Tyr705) (E2) 10µg/ml 40 Cell Signaling 9138
Mouse anti-human CA125 0.23µg/ml 32 Ventana 760-2610
HRP-conjugated secondary Unknown, proprietary reagent 8 Ventana 760-500
STATISTICAL ANALYSIS
Data are presented as mean± SEM. A probability level of p< 0.05
was adopted throughout to determine statistical significance.
Treatment groups were compared with the control group using
one-way ANOVA followed by Bonferroni or Dunnett’s multiple
comparison post-tests.
RESULTS
EFFECT OF SINGLE DOSE OF PACLITAXEL ON HEY TUMORS
Subcutaneous injection of mice with HEY cells resulted in the
formation of tumors within 5 days. Intraperitoneal injection of
paclitaxel (15 mg/kg of body weight) given 7 days post inocula-
tion of HEY cells was well tolerated by the mice. Treatment with
a single dose of paclitaxel did not result in any significant change
in the tumor volume compared to the control untreated mice
(Figures S1A–C in Supplementary Material).
Mouse tumors were excised and assessed by immunohisto-
chemistry. Xenografts that received paclitaxel treatment demon-
strated significantly enhanced staining for the CSC-like marker
CD117 and the embryonic stem cell maker Oct4 compared to
the control group (Figure S2 in Supplementary Material). These
results coincided with a significantly enhanced staining for CA125
in the mice treated with paclitaxel compared to the control group
(Figure S2 in Supplementary Material). The expression of CD117
and CA125 in untreated and paclitaxel-treated groups was con-
fined to the cytoplasm and cell membranes. The staining of
Oct4 was observed in the cytoplasm as well as in the nucleus in
both control and paclitaxel-treated mouse tumors (Figure S2 in
Supplementary Material).
VOLUME OF XENOGRAFTS GENERATED THROUGH ADMINISTRATION
OF A COMBINATION OF DAILY ORAL GAVAGES OF CYT387 WITH
WEEKLY INTRAPERITONEAL PACLITAXEL INJECTIONS
In the second approach, mice were treated with either paclitaxel
weekly, or CYT387 daily or treated with a combination of both or
observed without intervention (control group) 2 days after subcu-
taneous inoculation of HEY cells in both flanks of each mouse.
Mice were followed for a 28-day treatment period and tumor
volumes were analyzed at day 0 (before the start of treatment
regimens) versus day 28. A single tumor localized at the site of
inoculation (each flank) was obtained from each mouse. Mice in
FIGURE 1 | HEY xenograft volume in mice administered with or
without paclitaxel, CYT387 or a combination of paclitaxel and CYT387
(pac+CYT387). Average fold change in subcutaneous tumor volume.
Tumors were measured at day 0 (prior to treatment) and at the end of the
experiment (day 28). Data have been obtained from n=5 mice in each
group. Significant intergroup variations are indicated by *p<0.05,
**p<0.01.
the control group had an approximately 90-fold increase in tumor
volume at day 28 compared to day 0 (Figure 1). On the other hand,
tumors in mice treated with weekly doses of paclitaxel demon-
strated an approximately 30-fold increase in volume at day 28
compared to day 0. However, tumors in mice receiving daily doses
of CYT387 demonstrated only an approximately 20-fold increase
in tumor volume at day 28 compared to day 0. Remarkably, mice
that were treated with a combination of weekly paclitaxel and daily
CYT387 developed significantly smaller tumors when compared
to paclitaxel-treated and control groups, with a tumor fold change
of less than 10-fold at day 28 compared to day 0 (Figure 1). This
group had the smallest tumor volume of all the groups. The vol-
ume of the tumors produced in the CYT387 treatment group was
not significantly different than the paclitaxel treatment group.
PHENOTYPE OF XENOGRAFTS GENERATED THROUGHWEEKLY
SYSTEMIC PACLITAXEL AND DAILY ORAL GAVAGES OF CYT387
Xenografts were collected and analyzed using immunohistochem-
istry. The expression of phosphorylated (P) and total (T)-JAK2
and STAT3 was mostly confined to the cytoplasm. However,
some scattered nuclear staining was also evident. Staining for
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FIGURE 2 | Immunohistochemistry images of phosphorylated P-JAK2
andT-JAK2 staining in xenografts generated from subcutaneous
transplantation of HEY cells into mice administered with or without
paclitaxel, CYT387, or pac+CYT387. Tumor sections were stained with
antibodies specific for P-JAK2 and T-JAK2 as described in the Section
“Materials and Methods.” Magnification 200×, scale bar=10µM. Average
DAB intensity and proportion of staining of P-JAK2 or T-JAK2 in xenografts
was standardized to a negative control. The quantification was derived from
the staining of five independent xenografts in each group. Significant
intergroup variations are indicted by *p<0.05, **p<0.01, and ***p<0.001.
phosphorylated (P) and total (T) JAK2 and STAT3 was signifi-
cantly increased in tumors derived from mice receiving weekly
paclitaxel treatment compared to the control group (Figures 2
and 3). Daily administration of CYT387 on its own had no effect
on the phosphorylation of JAK2 or STAT3 compared to the con-
trol group, however it significantly decreased the endogenous
expression of T-STAT3 without any effect on the expression of
T-JAK2. Administration of daily CYT387 in conjunction with
paclitaxel treatment resulted in tumors that displayed a signifi-
cantly decreased staining of P-JAK2 and P-STAT3, compared to
paclitaxel only treated group. However, no effect on T-JAK2 or
T-STAT3 in the paclitaxel+CYT387 group compared to the pacli-
taxel only treated group could be observed. This suggests that
daily doses of CYT387 abolished the paclitaxel-induced activation
of the JAK2/STAT3 pathway without having a significant effect on
the expression of the total proteins (Figures 2 and 3).
Mice receiving paclitaxel developed tumors that displayed sig-
nificantly enhanced staining of the cell proliferation maker Ki67
when compared to the control group (Figure 4). The stain-
ing of Ki67 both in the control and treated groups was con-
fined to the nucleus. However, this enhanced nuclear staining of
Ki67 in response to paclitaxel administration was significantly
reduced when CYT387 was added in combination with pacli-
taxel (Figure 4). Moreover, mice that received daily CYT387 alone
developed tumors that displayed a significantly reduced Ki67
staining when compared to the paclitaxel only treatment group.
However, it had no effect on basal Ki67 staining (Figure 4).
Similar to that demonstrated in the first approach, tumors
derived from mice treated with paclitaxel alone displayed signifi-
cantly enhanced staining for CA125, the CSC-like marker CD117,
and the embryonic stem cell marker Oct4, when compared to
the control group (Figures 4 and 5). However, tumors derived
from mice treated with a combination of paclitaxel and CYT387
demonstrated significantly reduced staining of CD117, Oct4, and
CA125 compared to the paclitaxel-treated group (Figures 4 and 5).
CYT387 on its own had no effect on the basal expression of
CA125, CD117, and Oct4. These results suggest that the addition
of CYT387 abrogates the paclitaxel-induced CA125, CD117, and
Oct4 expression. The expression of CD117, Oct4, and CA125 was
present mostly in the cytoplasm and cell–cell membrane junctions.
Very little nuclear staining of Oct4 was also evident in xenografts
generated upon paclitaxel treatment.
Mice treated with paclitaxel developed tumors with signifi-
cantly enhanced expression of CD34+ cells when compared to the
control as well as the CYT387 treatment groups (Figure 6). The
addition of CYT387 to paclitaxel did not reduce the paclitaxel-
induced enhanced expression of CD34 which was mostly cyto-
plasmic.
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FIGURE 3 | Immunohistochemistry images of P-STAT3 andT-STAT3
staining in xenografts generated from subcutaneous transplantation of
HEY cells into mice administered with or without paclitaxel, CYT387, or
pac+CYT387. Tumor sections were stained with antibodies specific for
P-STAT3 and T-STAT3 as described in the Section “Materials and Methods.”
Magnification 200×, scale bar=10µM. Average DAB intensity and proportion
of staining of P-STAT3 or T-STAT3 in xenografts was standardized to a negative
control. The quantification was derived from the staining of five independent
xenografts in each group. Significant intergroup variations are indicted by
**p<0.01 and ***p<0.001.
To determine if changes in the embryonic stem cell marker
Oct4 seen at the protein level in mouse xenografts were consis-
tent at the mRNA level, q-PCR on cDNA prepared from RNA
extracted from mouse tumors was performed. An analysis of the
embryonic stem cell marker Oct4 revealed significantly enhanced
mRNA expression in tumors derived from mice treated with pacli-
taxel when compared to the control group (Figure 7). Consistent
with the Oct4 immunohistochemistry staining, the addition of
daily CYT387 treatment resulted in a significant reduction of
Oct4 mRNA in tumors compared to mice treated with paclitaxel
(Figure 7). Treatment with CYT387 alone did not result in any
significant change in the mRNA expression of Oct4 compared to
the control untreated group (Figure 7).
EFFECT OF ORAL GAVAGES OF CYT387 IN COMBINATION WITH
SYSTEMIC ADMINISTRATION OF PACLITAXEL ON
INTERLEUKIN-6-MEDIATED RESPONSES IN MOUSE XENOGRAFTS
We investigated whether the mRNA expression of IL-6 in the con-
trol tumor xenografts had any correlation with the mRNA levels of
invasion-associated genes such as CXCR4, MMP-2, and MMP-9 in
response to systemic administration of paclitaxel and oral gavages
of CYT387. Untreated control and paclitaxel administered mouse
tumors expressed human IL-6R as well as gp130 mRNA (Figure 8).
There were increased trends in the expression of IL-6, CXCR4,
MMP-2, and MMP-9 in the paclitaxel-treated group compared to
the control group. This increased trend however, did not receive
statistical significance between the two groups (Figure 8). When
the combination of paclitaxel and CYT387 was administered, the
mRNA expression of IL-6R, gp130, IL-6, CXCR4, MMP-2, and
MMP-9 did not change relative to the house keeping gene 18S
(Figure 8). On the other hand, CYT387 administration on its own
significantly increased the mRNA expression of MMP-2 compared
to the control group. An increased trend in the expression of MMP-
9 in the CYT387 treatment group compared to control was also
observed but it did not receive statistical significance (Figure 8).
No change in the mRNA expression of 18S was observed under
the same conditions (Figure S3 in Supplementary Material).
DISCUSSION
CYT387 is an orally available, potent small molecule inhibitor
of the JAK1/2 pathway currently undergoing Phase I/II clinical
trials for the treatment of myelofibrosis, a frequently diagnosed
fatal myeloproliferative disorder (36). CYT387 has so far been
the best candidate among the JAK inhibitors for the manage-
ment of myelofibrosis with the preliminary data showing signif-
icant responses with a low level of toxicity (http://www.gilead.
com/research/pipeline). CYT387 has demonstrated efficacy in a
JAK2V617F mutation-associated animal model where it inhib-
ited STAT3 functions associated with constitutively activated
JAK2, by normalizing inflammatory cytokines (37). In the murine
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FIGURE 4 | Immunohistochemistry images of Ki67 and CA125 staining in
xenografts generated from subcutaneous transplantation of HEY cells
into mice administered with or without paclitaxel, CYT387, or
pac+CYT387. Tumor sections were stained with antibodies specific for Ki67
and CA125 as described in the Section “Materials and Methods.”
Magnification 200×, scale bar=10µM. Average DAB intensity and proportion
of staining of Ki67 or CA125 in xenografts was standardized to negative
control. The experiments were performed using five independent samples in
each group. Significant intergroup variations are indicted by *p<0.05,
**p<0.01, and ***p<0.001.
JAK2V617F mutation-associated animal model, CYT387 also nor-
malized white cell counts, the hematocrit, and also restored the
normal spleen size (37). Preclinical analysis has shown CYT387
to be well tolerated in mice when administered orally at doses
up to 50 mg/kg of body weight, with no sign of overt toxicity
(37). Besides myeloproliferative disorders, CYT387 has the poten-
tial for the treatment of solid and hematological malignancies and
inflammatory conditions (36). In this proof of principle study,
we demonstrate the novel effect of CYT387 in combination with
paclitaxel in significantly suppressing the tumor growth greater
than that achieved by paclitaxel on its own. We also show suppres-
sion of the expression of CA125, Oct4, and CD117 by CYT387,
induced by the activation of JAK2/STAT3 pathway in response to
systemic paclitaxel administration in an ovarian xenograft model.
We have recently demonstrated that human ovarian cancer
cell lines as well as primary- and ascites-derived ovarian cancer
cells treated with cisplatin or paclitaxel generate a surviving resid-
ual population of cells which display enhanced expression of the
chemoresistant-associated markers ERCC1 and β-tubulin as well
as enhanced expression of CSC-like markers CD44, CD24, CD133,
CD117, and EpCAM, compared to parental untreated ovarian can-
cer cells (6, 9, 29). In addition, xenotransplantation studies showed
that chemotherapy-treated ovarian cancer cells generate signifi-
cantly larger tumor burden compared to untreated cells and retain
an enhanced stemness profile (29). This suggests that some CSC-
like and chemoresistant characteristics may be synchronously reg-
ulated in the residual cells that survived chemotherapy (7). In this
study, we provide further novel data which demonstrates that Oct4
and CD117 expression are enhanced in a mouse xenograft model
by intraperitoneal administration of chemotherapy (paclitaxel)
after the subcutaneous implantation of an ovarian cancer cell line.
We also demonstrate that the expression of Oct4 and CD117 in
tumors generated in response to multiple doses of chemotherapy
can be suppressed by the administration of a novel small molecule
JAK2-specific inhibitor CYT387. The advantage of using a sub-
cutaneous instead of the intraperitoneal model of ovarian tumor
is that it allows for the accurate measurement of tumor volume,
thus permitting the monitoring of tumor growth in response to
treatments.
In the first part of this study, we demonstrate that a single
systemic administration of paclitaxel 1 week after subcutaneous
implantation of ovarian cancer cells led to a tumor which had
a significant enhancement in the expression of Oct4 and CD117
within the 7 days post treatment. This enhancement in the Oct4
and CD117 expression coincided with a significant enhancement
of CA125 staining. Such dramatic changes in Oct4, CD117, and
CA125 staining had no bearing on tumor volume within the
7 days after paclitaxel administration. This suggests that although
no reduction in tumor volume was observed, a single dose of
paclitaxel treatment had imposed certain molecular changes in
the paclitaxel surviving residual tumor populations. This process
likely occurs consecutively in chemoresistant populations while
the chemosensitive populations undergo cell death in response to
paclitaxel treatment, a process that results in the eradication of
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FIGURE 5 | Immunohistochemistry images of CD117 and Oct4 staining
in xenografts generated from subcutaneous transplantation of HEY
cells into mice administered with or without paclitaxel, CYT387, or
pac+CYT387. Tumor sections were stained with antibodies specific for
CD117 and Oct4 as described in the Section “Materials and Methods.”
Magnification 200×, scale bar=10µM. Average DAB intensity and
proportion of staining of CD117 or Oct4 in xenografts was standardized to a
negative control. The experiments were performed using five independent
samples in each group. Significant intergroup variations are indicted by
***p<0.001.
FIGURE 6 | Immunohistochemistry images of CD34 staining in mice
xenografts from subcutaneous transplantation of HEY cells into mice
administered with or without paclitaxel, CYT387, or pac+CYT387.
Tumor sections were stained with antibodies specific for CD34 as
described in the Section “Materials and Methods.” Magnification 200×,
scale bar=10µM. Average DAB intensity and proportion of staining of
CD34 in xenografts was standardized to a negative control. The
experiments were performed using five independent samples in each
group. Significant intergroup variations are indicted by **p<0.01 and
***p<0.001.
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the majority of the tumor mass leaving behind theoretically the
CSC-enriched tumor initiating residual disease (38).
In the second approach, we demonstrate that weekly treatment
of paclitaxel over 28 days resulted in a dramatic reduction of the
mouse tumor volume as evidenced by a 30-fold increase in the
tumor volume in mice treated with paclitaxel when compared
to a ~90-fold increase in the volume in mice not receiving the
treatment. These results suggest that systemic weekly administra-
tion of paclitaxel-induced cytotoxic and anti-proliferative effects
on the tumor population restricting the growth of the tumors
FIGURE 7 |The mRNA expression of embryonic stem cell marker Oct4
in xenografts generated from subcutaneous transplantation of HEY
cells into mice administered with or without paclitaxel, CYT387, or a
combination of paclitaxel and CYT387 (pac+CYT). mRNA from
xenografts generated from the control group and treatment groups was
extracted, cDNA was prepared, and q-PCR for Oct4 was performed as
described in the Section “Material and Methods.” The resultant mRNA
levels were normalized to 18S mRNA. The experiments were performed
using five independent samples in triplicate. Significant intergroup
variations are indicated by **p< 0.01 and ***p<0.001.
compared to the control untreated tumors. However, CYT387 in
combination with paclitaxel was able to significantly reduce the
tumor volume greater than that can be achieved with paclitaxel
alone. This was achieved by using a concentration of CYT387
(5 mg/kg of body weight) that was one-tenth of that used in the
JAK2V617F mutation-associated animal model (50 mg/kg of body
weight) (37). In addition, CYT387 was administered twice a day in
the JAK2V617F mutation-associated animal model compared to
a single administration of the drug each day in our study. Hence,
it can be anticipated that increasing the concentration of CYT387
toward the same level as that used for the JAK2V617F mutation-
associated animal model would be well tolerated in our mouse
model and therefore has the potential of reducing tumor volume
further.
Tumor cells from mice which survived the paclitaxel treatment
were found to have an activated JAK2/STAT3 pathway and to have
significantly enhanced staining of embryonic stem cell transcrip-
tion factor Oct4 and CSC-like marker CD117. In addition, tumors
derived from mice treated with paclitaxel showed significantly
enhanced CA125 staining. These novel findings suggest that while
the tumor volume was smaller in paclitaxel-treated mice, these
tumor cells underwent specific molecular changes. As elevated
level of CA125 is the hallmark of ovarian cancer diagnosis and
frequently observed in recurrent disease, enhanced expression of
CA125 in paclitaxel-treated tumor cells may suggest priming of
the residual cells for recurrence.
The above in vivo mice data are consistent with the data
obtained after analyzing several stem cell markers in ovarian
tumor specimens collected at diagnosis (before treatment), after
chemotherapy treatment and at first recurrence (10). It has been
reported that CD133, CD44, and ALDH1A1 were present at
low numbers in primary tumors, however, this was found to
FIGURE 8 |The mRNA expression of IL-6, IL-6R, gp130, CXCR4, MMP-2,
and MMP-9 in xenografts generated from subcutaneous transplantation
of HEY cells into mice administered with or without paclitaxel, CYT387,
or pac+CYT. mRNA from xenografts generated from the control group and
treatment groups was extracted, cDNA was prepared, and q-PCR for IL-6,
IL-6R, gp130, MMP-2, MMP-9, and CXCR4 was performed as described in the
Section “Material and Methods.” The resultant mRNA levels were normalized
to 18S mRNA. The experiments were performed using four independent
samples in triplicate. Significant intergroup variations are indicated by
*p<0.05 and **p<0.01.
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increase in tumor specimens taken immediately after chemother-
apy treatment and then reduced to initial numbers in recurrent
tumors, suggesting that these so-called “CSC markers” iden-
tify “chemoresistant cells.” Such observations in animal mod-
els and clinical specimens suggest that chemotherapy treatment
may induce a “chemoresistant niche,” which protects residual
chemoresistant cells from cell death by promoting a microen-
vironment appropriate for the survival of CSCs. In that con-
text, CD133 positive colon CSCs have been shown to protect
themselves in vivo from apoptosis by autocrine secretion of
interleukin-4 (IL-4) (39). Paclitaxel treatment has been shown
to promote angiogenesis in tumors through the mobilization of
bone marrow-derived endothelial cells to tumors by an acute
drug-mediated release of stromal-derived factor-1 (SDF-1) and
G-CSF (40).
We also demonstrate that combining a daily dose of CYT387
with weekly paclitaxel treatment resulted in the development of
mouse tumors which had a significantly reduced activation of the
JAK2/STAT3 pathway compared to the group which received only
paclitaxel. This correlated with the significantly reduced expres-
sion of the paclitaxel-induced Oct4, CD117, CA125, and Ki67
expression. In addition, the tumor volume in the mice group
that received daily doses of CYT387 in combination with weekly
paclitaxel treatment was significantly smaller compared to the
treatment group that received only paclitaxel.
Our data also demonstrate a significantly enhanced accumula-
tion of CD34+ cells in tumors treated with paclitaxel compared
to control untreated tumors. CD34+ cells are a well-characterized
population of mesenchymal stem cells derived from bone marrow
or adipose tissue that have been used clinically to reconstitute the
hematopoietic system after radiation or chemotherapy (41). More
recently, CD34+ cells have also been shown to induce therapeutic
angiogenesis in animal models of myocardial, peripheral, and cere-
bral ischemia by direct incorporation of cells into the expanding
vasculature and/or paracrine secretion of angiogenic growth fac-
tors that supports the developing microvasculature (42). The fact
that CYT387 had no effect on the accumulation of CD34+ cells in
response to paclitaxel treatment indicates that CYT387 may not
have an effect on angiogenesis.
We have recently shown enhanced secretion of interleukin-6
(IL-6) and G-CSF and activation of associated downstream STAT3
pathway in several ovarian cancer cell lines in response to cis-
platin or paclitaxel treatments in vitro (7, 43). This suggests that
an “acute” drug-induced secretory response is promoted in the
tumor microenvironment following therapeutic administration,
which may have a negative impact on the therapeutic response
and act in favor of tumor cells by protecting them from the
cytotoxic effects of the chemotherapy. In addition, ovarian cancer-
related inflammation has recently been shown to be associated
with autocrine cytokine network mediated by tumor necrosis fac-
tor (TNF), CXCL12 (also known as SDF-1, ligand for CXCR4
receptor), and IL-6 (44). Autocrine secretion of IL-6 by tumor
cells or the associated infiltrated cells, not only promotes tumor
growth and invasion (45) but also facilitates chemoresistance (43,
46). A recent study has demonstrated metastatic and drug-resistant
recurrent ovarian tumors to have a significantly higher IL-6 expres-
sion compared to the matched primary tumors. In that study, the
use of a monoclonal IL-6 antibody was shown to suppress IL-6
induced STAT3 phosphorylation and nuclear translocation. This
resulted in the decreased expression of STAT3 downstream targets
such as Mcl-1 and sensitization of paclitaxel-resistant ovarian can-
cer cell lines to chemotherapy (27). Our study on the other hand,
showed no significant increase in human IL-6 mRNA expression
and its downstream metastasis-associated genes MMP-2, MMP-9,
and CXCR4 (receptor for CXCL12) in mouse tumors generated
during systemic administration of paclitaxel. This suggests that
the activation of STAT3 observed in the paclitaxel-treated mouse
xenografts may have been triggered by stimulatory agent(s) other
than IL-6.
The results from this study reflect the poorer outcomes for
patients receiving paclitaxel on its own as a first line chemother-
apy. However, these results also provide fresh hope for the
potential of a new combination therapy involving CYT387. For
the first time, we demonstrate that while the tumor volumes
are kept small as a result of paclitaxel treatment, populations
of tumor cells within the residual tumors retain the activated
JAK2/STAT3 pathway and are enriched in markers such as Oct4
and CD117. We propose that treatment of patients by first line
chemotherapy is in fact a process that enables chemotherapy sur-
viving cells to undergo molecular activation of the JAK2/STAT3
pathway. Our data suggests that the inhibition of JAK2/STAT3
pathway by CYT387 at a very low concentration in combina-
tion with paclitaxel can suppress the molecular changes induced
by chemotherapy in the residual tumors. This can result in a
smaller tumor volume than that achieved by the chemotherapy
alone. These preliminary “proof of concept” data warrant fur-
ther investigation of CYT387 in preclinical and clinical models.
One of the potential positive outcomes of combining CYT387
with the first line chemotherapy may be a longer disease-free sur-
vival period or a decreased incidence of recurrence or perhaps
even prevention of the inevitable emergence of fatal recurrent
disease.
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Figure S1 |Tumor volume in mice treated with a single dose of paclitaxel.
(A) Representative image of subcutaneous tumors in control and
paclitaxel-treated mice. (B) Fold change in tumor volume (mm3) at the end of
the study (7 days post treatment) was standardized to initial tumor volume prior
to receiving paclitaxel treatment. Data were obtained from n=3 mice in each
group. No significant difference between treatment groups was observed.
Figure S2 | Immunohistochemistry images of CD117, Oct4, and CA125
staining in HEY xenografts derived from mice treated with or without a
single dose of paclitaxel. Tumor sections were stained with antibodies specific
for CD117, Oct4, and CA125 as described in the Section “Materials and
Methods.” Average DAB intensity and proportion of staining for CD117, Oct4,
and CA125 in mouse tumors was standardized to a negative control. The
experiment was performed on three independent xenografts from each group.
Significant intergroup variations are indicated by ***p<0.001. Magnification
200×, scale bar=10µM.
Figure S3 |The mRNA expression of housekeeping gene 18S in xenografts
generated from subcutaneous transplantation of HEY cells into mice
administered with or without paclitaxel, CYT387, or pac+CYT. mRNA from
xenografts generated from the control group and treatment groups was
extracted, cDNA was prepared, and q-PCR for 18S was performed as described
in the Section “Materials and Methods.” The experiments were performed
using four independent samples in triplicate.
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